DDInter1008 DDInter1024
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Ketoconazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Lapatinib
Ketoconazole {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Lapatinib
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may lead to a major life threatening interaction when taken with {v} Lapatinib
Ketoconazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is associated with {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Lapatinib
Ketoconazole {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) regulates {v} (Gene) HERC6
HERC6 {u} (Gene) is upregulated by {v} (Compound) Lapatinib
Ketoconazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lapatinib
Ketoconazole {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Propofol
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Ketoconazole {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lapatinib
Ketoconazole {u} (Compound) causes {v} (Side Effect) Hepatotoxicity
Hepatotoxicity {u} (Side Effect) is caused by {v} (Compound) Bicalutamide
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Ketoconazole {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lapatinib
Ketoconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Ketoconazole (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Lapatinib (Compound)
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may lead to a major life threatening interaction when taken with Lapatinib
Ketoconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is associated with breast cancer (Disease) and breast cancer (Disease) is treated by Lapatinib (Compound)
Ketoconazole (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) regulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Lapatinib (Compound)
Ketoconazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Ketoconazole (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Propofol (Compound) and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Ketoconazole (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Ketoconazole (Compound) causes Hepatotoxicity (Side Effect) and Hepatotoxicity (Side Effect) is caused by Bicalutamide (Compound) and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Ketoconazole (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Lapatinib